NEK9 ablation rewires docetaxel resistance through induction of ERK-mediated cancer cell pyroptosis
Ansari, S. A.; Mohanty, S.; Mohapatra, P.; Rath, R.; Muduli, D.; Majumdar, S. K. D.; Swain, R. K.; Dash, R.
Show abstract
Docetaxel alone or in combination with other drugs is the most common chemotherapy regimen for several neoplasms including advanced OSCC. Unfortunately, chemoresistance leads to relapse and continued tumor growth. It is therefore important to explore the causative factors for docetaxel resistance. In this study, we performed a CRISPR-based kinome screening that identified Never In Mitosis Gene-A Related Kinase-9 (NEK9) as a major player of docetaxel resistance in OSCC, prostate, and pancreatic cancer lines. NEK9 expression was upregulated in tumor samples of chemotherapy non-responders compared to responder OSCC patients. Our validation data suggests selectively knocking out NEK9 sensitizes cancer cells to docetaxel. Mechanistically, we found that ablation of NEK9 induces DNA damage, activating ERK(p-T202/Y204) that leads to Gasdermin-E mediated Cancer Cell pyroptosis. The in-vitro kinase activity assay identified fostamatinib as a potent inhibitor of NEK9. The xenograft data suggest that fostamatinib restores docetaxel sensitivity and facilitates a significant reduction of tumor burden. Overall, our data suggests a novel combination of fostamatinib and docetaxel needs further clinical investigation in advanced OSCC.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis 97%
- Disassembly of hemidesmosomes promotes tumorigenesis in PTEN-negative prostate cancer by targeting plectin into focal adhesions 95%
- PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer 94%
Similar papers in this journal
- A subset of CB002 xanthine analogues bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53 95%
- NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model 95%
- ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer 94%
Similar papers in this journal
- An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer 96%
- Targeting LDHC dysregulates the cell cycle and improves sensitivity to cisplatin and olaparib 94%
- TPX2 expression promotes sensitivity to dasatinib in breast cancer by activating the YAP transcriptional signaling. 94%
Similar papers in this journal
- Targeting FEN1 to enhance efficacy of PARP inhibition in triple-negative breast cancer 94%
- A 'one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer 94%
- Physachenolide C induces complete regression of established murine melanoma tumors via apoptosis and cell cycle arrest 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.